William Blair & Company
TARS icon

William Blair & Company’s Tarsus Pharmaceuticals TARS Stock Holding History

William Blair & Company’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,416
Closed -$586K – 1899
2025
Q1 		$586K Sell
11,416
-15,814
-58% -$782K ﹤0.01% 1043
2024
Q4 		$1.51M Buy
+27,230
New +$1.24M ﹤0.01% 779

Other funds holding TARS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

William Blair & Company's TARS Position: Q2 2025 in Review

William Blair & Company sold out of Tarsus Pharmaceuticals (TARS) in Q2 2025, closing a stake of 11,416 shares — an estimated $586K sold.

William Blair & Company first reported a position in TARS in Q4 2024 and held it in 2 quarters. The position peaked at $1.51M in Q4 2024. 205 funds tracked by Wall St. Rank hold TARS as of Q2 2025.

  • William Blair & Company reported no remaining Tarsus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • William Blair & Company sold 11,416 Tarsus Pharmaceuticals shares in Q2 2025, an estimated $586K.
  • William Blair & Company first reported a position in Tarsus Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • William Blair & Company's Tarsus Pharmaceuticals position peaked at $1.51M in Q4 2024.
  • 205 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2025.

Based on William Blair & Company's 13F filing for Q2 2025, filed 24 Jul 2025.